title: [Clinical antiviral effects of Peg-IFNa-2a in patients with chronic hepatitis B].
abstract: OBJECTIVE
  To evaluate antiviral effects of Peg-IFNa-2a in patients with chronic hepatitis B.
  
  
  METHODS
  92 chronic hepatitis B patients were enrolled to receive the treatment with Peg-IFNa-2a 180 μg subcutaneous injection once weekly. The patients who did not get early response were divided into 3 groups: group 1, extend the treatment to 72 weeks; group 2, combined with nucleus(s)ide analogue (entecavir or adefovir) treatment; group 3, continue the treatment until 48 weeks. HBV DNA and quantitative HBsAg were assessed at baseline, week 12, 24, 36 and after 24 weeks follow-up.
  
  
  RESULTS
  Patients in group 1 had significantly higher SVR rate (78.3%) than patients in group 3 (38.1%, X2=7.33, P<0.05). The mean reduction of HBsAg in group 1 at 24 weeks of post-treatment follow up was higher than that in group 3 (t=2.11, P<0.05). In group 2 the mean reductions of HBV DNA at 24 weeks of post-treatment follow up were (3.9+/-1.1) log10 copy/ml and (3.7+/-1.3) log10 copy/ml respectively with combination of entecavir or adefovir, both of which were significantly higher than that in group 3(t=8.45 and 6.31, P<0.05); the SVR rates in the entecavir group and the adefovir group (83.3% and 85.7%, respectively) were significantly higher than that in group 3 (X2=8.20 and 7.78, P<0.05); the mean reductions of HBsAg in the entecavir group and the adefovir group [(0.8+/-0.5) log10 IU/ml and (0.9+/-0.3) log10 IU/ml, respectively ] were significantly greater than group 3[(0.4+/-0.3) log10 IU/ml, t=3.05 and 4.58, P<0.05]. The level of HBV DNA and C genotype were the main predictors of response.
  
  
  CONCLUSIONS
  Individualizing therapy by prolonging the duration of Peg-IFNa-2a treatment to 72 weeks or adding nucleoside analogues such as entecavir and adefovir in patients without early response may substantially increase the SVR rate and lead to the decrease of HBsAg.
authors.affiliation: Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun 130033, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Qing-tu-na-la
authors.initials: QT
authors.lastname: Si
authors.forename: Man-hua
authors.initials: MH
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Jiao
authors.forename: Yong-gui
authors.initials: YG
authors.lastname: Zhang
authors.forename: Shang-wei
authors.initials: SW
authors.lastname: Ji
authors.forename: Ping
authors.initials: P
authors.lastname: Zhao
authors.forename: Hong-hua
authors.initials: HH
authors.lastname: Guo
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Chang-yu
authors.initials: CY
authors.lastname: Zhou
authors.forename: Jiang-bin
authors.initials: JB
authors.lastname: Wang
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D063065:Organophosphonates; C413685:entecavir; D006147:Guanine; C053001:adefovir; D000225:Adenine